
ABCL stock has shown a significant increase in its market performance, with a year-over-year growth of 25%.
The stock's current price is around $12.50, a 15% increase from its 52-week low of $10.80.
ABCL's strong market performance can be attributed to its innovative products and services, which have gained significant traction in the market.
The company's revenue has also seen a notable surge, with a 30% increase in the past quarter alone.
Consider reading: S B I Card Share Price
See what others are reading: Acad Stock Quote
Stock Performance Overview
Abcl stock quote is a great way to get a snapshot of the company's performance. The stock's current market value is approximately $992,430,000.
The stock's price has been quite volatile, with a 52-week high of $5.60 and a 52-week low of $2.34. The current share price is $3.30.
In terms of growth, the stock has shown a significant decline over the past year, with a 1-year change of -37.50%. However, it's worth noting that the stock has shown some positive momentum in the past few months, with a 1-month change of 10.37% and a 3-month change of 18.71%.
Here's a breakdown of the stock's performance over the past year:
The stock's diluted EPS (TTM) is -$0.61, indicating a net loss for the company. The revenue growth YOY is -1.4%, showing a decline in revenue over the past year.
Financial Data
AbCellera Biologics estimates its revenue to reach $43 million in 2025, $64 million in 2026, $107 million in 2027, and $145 million in 2028.
The company's net profit is expected to be -$220 million in 2025, -$211 million in 2026, -$207 million in 2027, and -$184 million in 2028. This is based on the estimated net profit adjusted for special items, which will be -$142 million in 2025, -$89 million in 2026, -$70 million in 2027, and -$31 million in 2028.
Research and development expenses are expected to increase to $175 million in 2025, $184 million in 2026, $197 million in 2027, and $204 million in 2028.
You might enjoy: Cloudflare Stock Quote
Estimates in USD
Estimates in USD are a crucial aspect of financial data, providing insight into a company's future performance. AbCellera Biologics' revenue is estimated to reach $43 USD in 2025, $64 USD in 2026, $107 USD in 2027, and $145 USD in 2028.
The number of analysts providing estimates for AbCellera Biologics' revenue varies, with 10 analysts providing estimates for 2025, 3 analysts for 2026, and 3 analysts for 2027. The average revenue estimate for 2025 is $8 USD, increasing to $12 USD in 2026 and $13 USD in 2027.
A key indicator of a company's financial health is its earnings per share (EPS). AbCellera Biologics' EPS is estimated to be -$0.57 USD in 2025, -$0.49 USD in 2026, -$0.22 USD in 2027, and -$0.08 USD in 2028.
Here's a summary of the estimated financial data for AbCellera Biologics:
The number of analysts providing EPS estimates for AbCellera Biologics is also worth noting, with 9 analysts providing estimates for 2025, 3 analysts for 2026, and 3 analysts for 2027.
Shareholder Returns
Shareholder Returns are a crucial aspect of a company's financial health.
Over the past 7 days, ABCL's shareholder returns were 7.8%, significantly higher than the US Life Sciences industry's 0.5% return.
The 1-year return for ABCL was -37.5%, underperforming the US Life Sciences industry, which returned 1.1% over the same period.
ABCL's 1-year return was also lower than the US Market's 23.7% return.
Here's a comparison of ABCL's returns with the US Life Sciences industry and the US Market over the past 7 days and 1 year:
Frequently Asked Questions
What is the forecast for ABCL?
According to 7 Wall Street analysts, the average 12-month price target for ABCL is $8.25, representing a 175.92% increase from its current price of $2.99
What is the price target for ABCL in 2025?
The price target for ABCL is estimated to be between $5.00 and $28.00 USD, with an average estimate of $12.29 USD. For the most up-to-date and accurate information, please refer to the latest analyst reports.
Featured Images: pexels.com


